Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Sarel Halachmi, Ilan Leibovitch, Amnon Zisman, Avi Stein, Shalva Benjamin, Ami Sidi, Ron Knickerbocker, Michal Limor, Yan Moore | ||||||||||||
Title | Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC). | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.499 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 499-499 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BC-819 | BC819|BC 819|Inodiftagene vixteplasmid | BC-819 (Inodiftagene vixteplasmid) is a recombinant DNA construct encoding an engineered diphtheria toxin that is specifically toxic to bladder cancer cells (Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 499-499). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|